SCHEMBL4880802

SCHEMBL4880802

CSc1cccc(Nc2ncc(F)cc2C(=O)NC2CCC(NC(=O)O)CC2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.51
RXFP1 Q9HBX9 1/20 0.51
CNR2 P34972 1/20 0.43
EGFR P00533 1/20 0.42
BTK Q06187 1/20 0.42
PDE4B Q07343 2/20 0.42
PDE4D Q08499 2/20 0.42
PIM1 P11309 1/20 0.40
PIM2 Q9P1W9 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MAPK1 P28482 2/20 0.40
HPGD P15428 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PDE4A P27815 1/20 0.40
ITK Q08881 2/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4880785 1.00 MAPT (0.51) MAPTRXFP1CNR2EGFRBTK
SCHEMBL3022489 0.85 EGFR (0.44) MAPTCNR2EGFRBTKPDE4B
SCHEMBL3022482 0.85 EGFR (0.44) MAPTCNR2EGFRBTKPDE4B
SCHEMBL4874437 0.84 CAMK1D (0.42) CNR2EGFRBTKPDE4BPDE4D
SCHEMBL4874446 0.84 CAMK1D (0.42) CNR2EGFRBTKPDE4BPDE4D
SCHEMBL4874399 0.82 MEN1 (0.49) MAPTSMN1; SMN2MAPK1HPGDMEN1
SCHEMBL4879896 0.82 PDE4B (0.49) CNR2EGFRBTKPDE4BPDE4D
SCHEMBL4879890 0.82 PDE4B (0.49) CNR2EGFRBTKPDE4BPDE4D
SCHEMBL3026238 0.77 CHRNA7 (0.44)
SCHEMBL3026234 0.77 CHRNA7 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227797-A1 Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases ASTRAZENECA AB (SE) 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227797-A1 Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases PDE4A, PDE4B, PDE5A MAPT 2873/4885RXFP1 2279/4885CNR2 3092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.